<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of PRAP-1, a Fab-fragment of a PAI-1-inhibiting polyclonal antibody, on <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size and arterial blood flow was studied in a rat model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It was shown that exposure of the carotid artery to <z:chebi fb="0" ids="30808">FeCl3</z:chebi> led to the rapid formation of an occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> with a <z:mp ids='MP_0000002'>morphology</z:mp> similar to that of arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> found in humans </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="48669">Tranexamic acid</z:chebi> (50 mg/kg), an inhibitor of fibrinolysis, increased <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size (p = 0.014) when given intravenously (i.v.) prior to the <z:chebi fb="0" ids="30808">FeCl3</z:chebi>-exposure </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> (1000 U), when given i.v. after <z:chebi fb="0" ids="30808">FeCl3</z:chebi>, did not affect the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size per se, but caused a reduction in the interindividual variation of the size of the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> (p &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, <z:chebi fb="5" ids="28304">heparin</z:chebi> was included in <z:hpo ids='HP_0000001'>all</z:hpo> the subsequent experiments </plain></SENT>
<SENT sid="5" pm="."><plain>An i.v. infusion of t-PA (1 mg/kg/h), starting before <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, induced a 3.3 fold increase in the perfusion rate (p = 0.006) and a 67% reduction in the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>PRAP-1, an inhibitor of rat PAI-1 activity, was given i.v. as a bolus followed by an infusion </plain></SENT>
<SENT sid="7" pm="."><plain>Two doses of PRAP-1 were studied (7.5 and 15 mg/kg/h), and the administration of the PAI-1 inhibitor was started 10 min before <z:chebi fb="0" ids="30810">FeCl3 </z:chebi></plain></SENT>
<SENT sid="8" pm="."><plain>The lower PRAP-1 dose caused a 3.8 fold increase in perfusion rate (p = 0.036), a 1.44 fold increase in the time to occlusion (p = 0.034), and the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size was decreased by 18% (p = 0.104) </plain></SENT>
<SENT sid="9" pm="."><plain>The corresponding effects of the high PRAP-1 dose were a 6.5 fold increase in perfusion rate (p &lt; 0.001), a 1.6 fold increase in time to occlusion (p = 0.038) and a 32% reduction in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size (p = 0.016) </plain></SENT>
<SENT sid="10" pm="."><plain>It is concluded that an inhibitor of PAI-1 activity, PRAP-1, caused a moderate decrease in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size and partly restores blood flow in a rat model of arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>This finding suggests a potential role for an inhibitor of PAI-1 in the treatment of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
</text></document>